RNAi-mediated NANOG knockdown has been successfully used to improve the chemosensitivity of HepG2 liver cancer cells to doxorubicin [52] or oesophageal cancer cells to cisplatin [53]. The gene discussed is NANOG; the disease is liver cancer.